Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study
The Feasibility, Safety and Efficacy Evaluation of Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System for the Treatment of Coronary Heart Disease: a First-in-man Study
Sponsor: Shanghai Bio-heart Biological Technology Co., Ltd.
This NA trial investigates Heart Diseases and is currently ongoing. Shanghai Bio-heart Biological Technology Co., Ltd. leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting NA
-
Dec 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Not Yet Recruiting → Active Not Recruiting · Phase: PHASE1 → NA
▶ Show 2 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Bio-heart Biological Technology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.